Shareholder update - year ended 31 December 2020
Filed with ASX ·
6ix hasn’t read this filing yet.
Telix Pharmaceuticals Limited on 6ix
Earlier from Telix Pharmaceuticals
- Czech Republic Grants National Authorisation for TLX591 Kit
- Appendix 4C and Activities Report for December 2020 Quarter
- New Drug Submission filed with Health Canada for TLX591-CDx
- IP Agreement with U Southampton for access to TRALA data
- Telix Completes Acquisition of TheraPharm GmbH
Later from Telix Pharmaceuticals
- Appendix 4E - Results for announcement to the market
- S&P DJI Announces March 2021 Quarterly Rebalance
- TGA commences priority evaluation process for Illuccix
- Launch of International NOBLE Registry for SPECT Imaging
- Japanese Renal Cancer Imaging Trial Meets Study Objectives
Follow Telix Pharmaceuticals into a list and get an email when it puts out news.
Follow Telix Pharmaceuticals